biologics

Pharmalot By Ed Silverman

Will the ‘patent dance’ cause Amgen to temporarily pull a biosimilar off the market?

Biotech By Elizabeth Cooney

Startup Spotlight: Going after immune regulators when they cause disease instead of prevent it

First Opinion By Sean McGowan

Five years on, biosimilars need support from all health care players

First Opinion By Leah Christl

From bench to bedside, biologics require excellence at every stage

First Opinion By Michelle Hoffmann

Biosimilars: the cure for sky-high drug prices or a stake in the heart of innovation?

Business By Associated Press

Samsung’s biotech unit debuts in Seoul. Here’s what to know

In the Lab By Eric Boodman

Freeze-dried drug factories could make a slew of medicines — just add water

Pharmalot By Ed Silverman

Biosimilar names may affect pharmacist dispensing habits

Pharmalot By Ed Silverman

Some biosimilars are just as good as some pricey biologics

Pharmalot By Ed Silverman

Teva, one of the biggest generic makers, joins the brand-name club

Pharmalot By Ed Silverman

Court ruling on biosimilar launches could increase health care costs

Pharmalot By Ed Silverman

Bill introduced to speed cheaper versions of pricey biologics to market

Pharmalot By Ed Silverman

Supreme Court asks Obama administration for views on biosimilar rules

Pharmalot By Ed Silverman

Unintended twist in Obamacare may cost some Medicare patients more for biosimilars

Pharmalot By Ed Silverman

FDA proposes biosimilar labeling that favors generic drug makers